Hutchmed
46
10
12
23
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
21.7%
10 terminated/withdrawn out of 46 trials
69.7%
-16.8% vs industry average
9%
4 trials in Phase 3/4
39%
9 of 23 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (46)
Phase III Study on HMPL-523 for Treatment of ITP
Role: lead
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Role: lead
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Role: lead
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Role: lead
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Role: collaborator
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Role: lead
Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets
Role: lead
Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans
Role: lead
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Role: lead
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Role: lead
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Role: lead
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Role: lead
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
Role: lead
Open-label Study of Surufatinib in Japanese Patients
Role: lead
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Role: lead
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Role: lead
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Role: lead
Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
Role: lead
Open-Label Surufatinib in European Patients With NET
Role: lead
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Role: lead